Our main goal is to correlate key proteomic and genomic alterations in melanomas with responses to next-generation targeted therapy. The new treatment opportunities and the remarkable heterogeneity of melanoma tumors require better profiling of tumor sub-types to achieve efficient selection of patients for targeted therapies. We will focus on responses to BRAF inhibitors (BRAFi) such as PLX4032/RG7204/ Vemurafenib and GSK2118436. The studies will include novel kinase inhibitors developed by Plexxikon to overcome the """"""""paradoxical effect"""""""" of BRAFi (i.e., stimulation of cells with wild type BRAF), termed """"""""paradox breakers"""""""" (PLX-PB). Freshly isolated tumors will be characterized at base line before treatment and at the time of disease progression employing multiplex-phosphoproteomic assays, high throughput sequencing of coding regions (Exome-Seq), and gene expression arrays to establish a subset of indicators that correlate with short (<6 months) versus durable (s 12 months) response to the drug. We will assess the characteristics of tumors poorly responsive to BRAFi compared to those with durable response, relapsing over a year after treatment. We expect to identify mechanism(s) of resistance that can be used to devise alternative treatments. The major translational outcome ofthis work is classification of melanomas by phospho-proteomic/genomic/gene expression aberrations that show an association between treatment and response that will lead to development of assays for selection of patients for targeted therapies. In addition, the project will facilitate clinical trials of novel BRAFv600 kinase inhibitors.
Aim 1 : To correlate phosphoproteomic, genomic and gene expression aberrations with resistance to BRAFi.
Aim 2 : To perform functional analyses on the best markers associated with treatment response employing melanoma cells in culture.
Aim 3 : To conduct a Phase I clinical trial with next-generation """"""""paradox-breakers"""""""" (PB) BRAFi developed by Plexxikon Inc. We will compare tumor profiles of PLX-PB response to those revealed in Aims 1 and 2.
The experience with PLX4032, an efficient inhibitor of cells harboring the BRAF[V600E/K] mutation, and other targeted therapies demonstrated that while responses have been observed, they are of limited duration due to emergence of tumor resistance. Therefore, there is a need to better define the network of activated kinases and intermediates that may interfere with the selected treatment in order to provide markers for better patient selection and for effective combination therapy.
|Brash, Douglas E (2016) UV-induced Melanin Chemiexcitation: A New Mode of Melanoma Pathogenesis. Toxicol Pathol 44:552-4|
|Premi, Sanjay; Brash, Douglas E (2016) Chemical excitation of electrons: A dark path to melanoma. DNA Repair (Amst) 44:169-77|
|Jiang, Yu; Shi, Xingjie; Zhao, Qing et al. (2016) Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics 107:223-30|
|Cyrus, Nika; Mai-Anh Bui, Christine; Yao, Xiaopan et al. (2016) Density and Polarization States of Tumor-Associated Macrophages in Human Cutaneous Squamous Cell Carcinomas Arising in Solid Organ Transplant Recipients. Dermatol Surg 42 Suppl 1:S18-23|
|Robles-Espinoza, Carla Daniela; Roberts, Nicola D; Chen, Shuyang et al. (2016) Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 7:12064|
|Gibson, Juliet F; Huang, Jing; Liu, Kristina J et al. (2016) Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-VÎ² chain restriction. J Am Acad Dermatol 74:870-7|
|Wang, Xuefeng; Chen, Mengjie; Yu, Xiaoqing et al. (2016) Global copy number profiling of cancer genomes. Bioinformatics 32:926-8|
|Wang, Yu; Zhao, Yinjun; Ma, Shuangge (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16:691|
|Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2016) FISH Panel for Leukemic CTCL. J Invest Dermatol :|
|Halaban, Ruth; Krauthammer, Michael (2016) RASopathy Gene Mutations in Melanoma. J Invest Dermatol 136:1755-9|
Showing the most recent 10 out of 134 publications